Development of a stability-indicating HPLC method and a dissolution test for rivaroxaban dosage forms

• Autorzy: Souri E. , Mottaghi S. , Zargarpoor M. , Ahmadkhaniha R. , Jalalizadeh H.
• Języki publikacji: EN

Abstrakty

EN

Rivaroxaban is an inhibitor of factor Xa, which is used as an oral anticoagulant for the prevention of thromboembolism. The objective of this study was to develop a stability-indicating high-performance liquid chromatographic method for the quantitative determination of rivaroxaban in pharmaceutical dosage forms. Rivaroxaban was subjected to acidic, basic, oxidative, photolytic, and thermal conditions for forced stress degradation studies. Considerable degradation was observed in all stress degradation tests. Rivaroxaban and its degradation products were separated on a Nova-Pak C8 column utilizing a mixture of acetonitrile and KH2PO4 50 mM (pH 3.0) (40:60, v/v) as the mobile phase, and the chromatogram was recorded at 270 nm using a general ultraviolet (UV) detector. The developed method was linear over the concentration range of 1–50 μg mL−1 showing acceptable within-day and between-day precision and accuracy values (CV <2% and Error <2%). The dissolution profile of rivaroxaban tablets was also studied in the presence of a surfactant using optimized conditions. The validated method was successfully used for the determination of rivaroxaban in dosage forms and also in dissolution medium indicating the specificity of the assay method.

Słowa kluczowe

EN

rivaroxaban; HPLC; stability-indicating; stress degradation; dissolution condition

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2016
• Tom: Vol. 28, no. 3
• Strony: 347--361
• Opis fizyczny: Bibliogr. 12 poz., rys., tab.

Twórcy

autor

Souri E.

• Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran 14155-6451, Iran
• Drug Design and Development Research Center, Tehran University of Medical Sciences, Tehran 14155-6451, Iran

autor

Mottaghi S.

• Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran 14155-6451, Iran
• Drug Design and Development Research Center, Tehran University of Medical Sciences, Tehran 14155-6451, Iran

autor

Zargarpoor M.

autor

Ahmadkhaniha R.

• Department of Human Ecology, School of Public Health, Tehran University of Medical Sciences, Tehran 1417613151, Iran

autor

Jalalizadeh H.

• Department of Research and Development, Osvah Pharmaceutical Co., Tehran, Iran

Bibliografia

• [1] E. Perzborn, J. Strassburger, A. Wilmen, J. Pohlmann, S. Rochrig, K. H. Schlemmer, and A. Straub, J. Thromb. Haemostasis, 3, 514–521 (2005)
• [2] D. Kubitza and S. Haas, Expert Opin. Invest. Drugs, 15, 843–855 (2006)
• [3] B. J. Biemond, E. Perzborn, P. W. Friederich, M. Levi, U. Buetehorn, and H. R. Buller, Thromb. Haemostasis, 97, 471–477 (2007)
• [4] G. Rohde, J. Chromatogr. B., 872, 43–50 (2008)
• [5] C. Weinz, T. Schawarz, D. Kubitza, W. Mueck, and D. Lang, Drug Metab. Dispos., 37, 1056–1064 (2009)
• [6] M. Celebier, T. Recber, E. Kocak, and S. Altinaz, Braz. J. Pharm. Sci., 49, 359–366 (2013)
• [7] A. Kasad Pinaz and K. S. Muralikrishna, Asian J. Pharm. Anal., 3, 62–65 (2013)
• [8] I. B. Lories, A. Mostafa, and M. A. Girges, J. Chromatogr. Sep. Tech., 4, 9 (2013)
• [9] J. W. More and H. H. Flanner, Pharm. Technol., 20, 64–74 (1996)
• [10] FDA, Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms, Food and Drug Administration, Rockville, MD, 1997
• [11] K. Takacs-Novak, V. Szoke, G. Volgyi, P. Horvath, R. Ambrus, and P. Szabo-Revesz, J. Pharm. Biomed. Anal., 83, 279–285 (2013)
• [12] V. P. Shah, C. Noory, B. McCullough, S. Clarke, R. Everett, H. Naviasky, B. N. Srinivasan, D. Fortman, and J. P. Skelly, Int. J. Pharm., 125, 99–106 (1995)

Uwagi

PL

Opracowanie ze środków MNiSW w ramach umowy 812/P-DUN/2016 na działalność upowszechniającą naukę.